What changed in the March 16, 2026 GPCR analyst rating updates?

On March 16, 2026 both William Blair and Leerink Partners maintained an Outperform on Structure Therapeutics. The firms reiterated confidence in the oral GLP-1 program without issuing new price targets.

Do these GPCR analyst rating maintenances include new price targets?

No. The March 16, 2026 notes from William Blair and Leerink maintained Outperform but did not publish new GPCR price target updates. Analysts focused on clinical and commercial potential.

How should investors interpret the GPCR analyst rating signals?

Maintained Outperform ratings suggest analysts expect outperformance versus peers, but investors should weigh clinical milestones, execution risk, and lack of new price targets before acting on GPCR analyst rating notes.

What is Meyka AI’s view on the GPCR analyst rating and stock?

Meyka AI rates GPCR with a grade of B, reflecting benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. This grade supports the positive GPCR analyst rating but is not investment advice.

Analyst Ratings

William Blair, Leerink Maintain Outperform on Structure Therapeutics (GPCR) Mar 2026

ByHuzaifa Zahoor March 17, 2026

On March 16, 2026 we saw a clear GPCR analyst rating outcome: William Blair and Leerink Partners each maintained an Outperform on Structure Therapeutics Inc. (GPCR). These same-day confirmations keep analyst sentiment positive after the company’s recent topline news. The dual maintenances came at 10:32 AM and 11:51 AM ET and coincided with modest intraday share weakness. We track how the comments from both firms connect to aleniglipron development, investor expectations, and short-term stock moves.